{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:09:55Z","timestamp":1789704595768,"version":"4.0.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017407","name":"Universidad Internacional de La Rioja","doi-asserted-by":"publisher","award":["I25-003"],"award-info":[{"award-number":["I25-003"]}],"id":[{"id":"10.13039\/100017407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jmii.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:29:19Z","timestamp":1783628959000},"page":"531-539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Is the HIV-2 pandemic going extinct 40 years after virus discovery?"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4624-5199","authenticated-orcid":false,"given":"Vicente","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berenger","family":"Konan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Segla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Moreno-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"de Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2026.07.004_bib1","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1056\/NEJM198705073161903","article-title":"Human immunodeficiency virus type 2 infection associated with AIDS in West Africa","volume":"316","author":"Clavel","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(85)92556-5","article-title":"Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of West Africa","volume":"2","author":"Barin","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2026.07.004_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1126\/science.2425430","article-title":"Isolation of a new human retrovirus from West African patients with AIDS","volume":"233","author":"Clavel","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.jmii.2026.07.004_bib4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/326662a0","article-title":"Genome organization and transactivation of the human immunodeficiency virus type 2","volume":"326","author":"Guyader","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2026.07.004_bib5","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.1993.03510170073033","article-title":"Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic","volume":"270","author":"DeCock","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2026.07.004_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200007010-00011","article-title":"Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections","volume":"24","author":"Shanmugam","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2026.07.004_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1096-9071(200005)61:1<111::AID-JMV18>3.0.CO;2-W","article-title":"Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load","volume":"61","author":"Soriano","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib8","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1097\/00002030-200312050-00006","article-title":"Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort","volume":"17","author":"Matheron","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2334-8-21","article-title":"Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database","volume":"8","author":"Ruelle","year":"2008","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf336","article-title":"Insights to a cure: unique controller phenotypes in the Rotterdam HIV-2 cohort","volume":"12","author":"Hensley","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1097\/QAD.0000000000001485","article-title":"HIV type 2 epidemic in Spain: challenges and missing opportunities","volume":"31","author":"de Mendoza","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1056\/NEJM198904133201501","article-title":"HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil","volume":"320","author":"Cortes","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/0255-0857.62485","article-title":"Frequency of HIV type 2 infections among blood donor population from India: a 10-year experience","volume":"28","author":"Kannangai","year":"2010","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jmii.2026.07.004_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15585\/mmwr.mm6903a2","article-title":"Trends in HIV-2 diagnoses and use of the HIV-1\/HIV-2 differentiation test - united States, 2010-2017","volume":"69","author":"Peruski","year":"2020","journal-title":"MMWR (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.jmii.2026.07.004_bib15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1126\/science.287.5453.607","article-title":"AIDS as a zoonosis: scientific and public health implications","volume":"287","author":"Hahn","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jmii.2026.07.004_bib16","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.72.5.3872-3886.1998","article-title":"Simian immunodeficiency virus replicates to high level in sooty mangabeys without inducing diseases","volume":"72","author":"Rey-Cuille","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib17","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1073\/pnas.83.14.5286","article-title":"Isolation of a T lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys)","volume":"83","author":"Fultz","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jmii.2026.07.004_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/339389a0","article-title":"An African primate lentivirus (SIVsm) closely related to HIV-2","volume":"339","author":"Hirsch","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2026.07.004_bib19","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1128\/JVI.79.4.2631-2636.2005","article-title":"Detection and partial characterization of simian immunodeficiency virus SIVsm strains from bush meat samples from rural Sierra Leone","volume":"79","author":"Apetrei","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib20","doi-asserted-by":"crossref","first-page":"12515","DOI":"10.1128\/JVI.79.19.12515-12527.2005","article-title":"Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Ta\u00ef Forest, C\u00f4te d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2","volume":"79","author":"Santiago","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib21","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1128\/jvi.70.6.3617-3627.1996","volume":"70","author":"Chen","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/358495a0","article-title":"Human infection by genetically diverse SIVSM-related HIV-2 in West Africa","volume":"358","author":"Gao","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2026.07.004_bib24","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1073\/pnas.0936469100","article-title":"Tracing the origin and history of the HIV-2 pandemic","volume":"100","author":"Lemey","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jmii.2026.07.004_bib25","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1586\/14787210.2013.825443","article-title":"The origin and molecular epidemiology of HIV","volume":"11","author":"Peeters","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jmii.2026.07.004_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.meegid.2016.08.010","article-title":"HIV-2 molecular epidemiology","volume":"46","author":"Visseaux","year":"2016","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jmii.2026.07.004_bib27","doi-asserted-by":"crossref","first-page":"veab024","DOI":"10.1093\/ve\/veab024","article-title":"HIV- 2 diversity displays two clades within group A with distinct geographical distribution and evolution","volume":"7","author":"Visseaux","year":"2021","journal-title":"Virus Evol"},{"key":"10.1016\/j.jmii.2026.07.004_bib28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1099\/vir.0.038638-0","article-title":"Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A","volume":"93","author":"Faria","year":"2012","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/088922299311132","article-title":"Predominance of HIV type 2 subtype B in Abidjan, Ivory Coast","volume":"15","author":"Pieniazek","year":"1999","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jmii.2026.07.004_bib30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0974-777X.188592","article-title":"Phylogenetic analysis of human immunodeficiency virus type 2 group B","volume":"8","author":"Cella","year":"2016","journal-title":"J Global Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1742-4690-5-103","article-title":"Isolation of a new HIV-2 group in the US","volume":"5","author":"Smith","year":"2008","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmii.2026.07.004_bib32","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1097\/01.aids.0000432443.22684.50","article-title":"Evidence for continuing cross-species transmission of SIVsmm to humans: characterization of a new HIV-2 lineage in rural Cote d'ivoire","volume":"27","author":"Ayouba","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00554-18","article-title":"Inhibitory effects of HIV-2 vpx on replication of HIV-1","volume":"92","author":"Mahdi","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib34","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2352-3018(18)30094-8","article-title":"90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2","volume":"5","author":"Gottlieb","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2026.07.004_bib35","first-page":"151","article-title":"The burden of HIV-1 and HIV-2 epidemics in Ivory Coast","volume":"26","author":"Konan","year":"2024","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jmii.2026.07.004_bib36","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/QAD.0000000000001827","article-title":"HIV-2 continues to decrease, whereas HIV-1 is stabilizing in Guinea-Bissau","volume":"32","author":"Olesen","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib37","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/QAD.0000000000000844","article-title":"Predicting the extinction of HIV-2 in rural Guinea-Bissau","volume":"29","author":"Fryer","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/088922201750102481","article-title":"Molecular evidence of homosexual transmission of HIV type 2 in Spain","volume":"17","author":"Cilla","year":"2001","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jmii.2026.07.004_bib39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0140-6736(05)60978-6","article-title":"Vertical transmission of HIV-2","volume":"349","author":"Cavaco-Silva","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2026.07.004_bib40","series-title":"Laboratory testing for the diagnosis of HIV infection: updated recommendations","year":"2014"},{"key":"10.1016\/j.jmii.2026.07.004_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1423-0410.1996.7110067.x","article-title":"Serial dilutions on synthetic peptide-based assays can resolve dual seroreactivity to HIV-1 and HIV-2","volume":"71","author":"Soriano","year":"1996","journal-title":"Vox Sang"},{"key":"10.1016\/j.jmii.2026.07.004_bib42","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1086\/431204","article-title":"Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2","volume":"41","author":"Rod\u00e9s","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib43","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jmii.2026.07.004_bib44","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/S2352-3018(18)30254-6","article-title":"Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study","volume":"6","author":"Esbjornsson","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2026.07.004_bib45","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1086\/315010","article-title":"Lower HIV-2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2","volume":"180","author":"Popper","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib46","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0140-6736(90)90920-Z","article-title":"Symptomatic HIV-2 primary infection","volume":"335","author":"Besnier","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2026.07.004_bib47","first-page":"934","article-title":"HIV-1 and HIV-2 AIDS in African patients living in Paris","volume":"11","author":"Matheron","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1046\/j.1365-3156.2000.00627.x","article-title":"AIDS caused by HIV-1 and HIV-2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal","volume":"5","author":"Ndour","year":"2000","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jmii.2026.07.004_bib49","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/00002030-199309000-00002","article-title":"The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels","volume":"7","author":"Sheppard","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib50","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJM199906033402203","article-title":"Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1 \u2014 a report from the Sydney Blood Bank Cohort","volume":"340","author":"Learmont","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib51","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00002030-200405210-00004","article-title":"Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection","volume":"18","author":"Rod\u00e9s","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19970-3","article-title":"Elite controllers long-term non-progressors present improved survival and slower disease progression","volume":"12","author":"Capa","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2026.07.004_bib53","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1196-1240","article-title":"The role of a mutant CCR5 allele in HIV-1 transmission and disease progression","volume":"2","author":"Huang","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/QAD.0b013e328344892e","article-title":"Immunology group of the ANRS CO5 HIV-2 cohort. Long-term non-progressors and elite controllers in the ANRS CO5 HIV-2 cohort","volume":"25","author":"Thi\u00e9baut","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib55","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1126\/science.272.5265.1167","article-title":"Prognosis in HIV-1 infection predicted by the quantity of virus in plasma","volume":"272","author":"Mellors","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jmii.2026.07.004_bib56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/COH.0000000000000299","article-title":"Mortality and survival patterns of people living with HIV-2","volume":"11","author":"Tchounga","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib57","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/JCM.00126-08","article-title":"ACHIEV2E Collaboration on HIV-2 Infection Study Group. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006","volume":"46","author":"Damond","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2026.07.004_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1128\/JCM.01613-06","article-title":"Quantitative detection of plasma HIV type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1)","volume":"45","author":"Rod\u00e9s","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2026.07.004_bib59","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1128\/JCM.02389-10","article-title":"ACHI(E)V(2E) Study Group. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study","volume":"49","author":"Damond","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2026.07.004_bib60","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/00002030-199311000-00002","article-title":"Cellular and plasma viral load in patients infected with HIV-2","volume":"7","author":"Simon","year":"1993","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib61","first-page":"44","article-title":"Antiretroviral therapy for HIV-2 infection in non-endemic regions","volume":"22","author":"de Mendoza","year":"2020","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jmii.2026.07.004_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0317223","article-title":"Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients","volume":"20","author":"Koffi","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2026.07.004_bib63","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1093\/ije\/dyad065","article-title":"Cohort Profile Update: the Bissau HIV Cohort - a cohort of HIV-1, HIV-2 and co-infected patients","volume":"52","author":"Dutschke","year":"2023","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jmii.2026.07.004_bib64","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcv.2009.03.011","article-title":"Virological and immunological responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, C\u00f4te d'ivoire","volume":"45","author":"Borget","year":"2009","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jmii.2026.07.004_bib65","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"ACHIEV2E Collaboration Study Group. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E Collaboration Study Group","volume":"52","author":"Benard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib66","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2013.12.001","article-title":"Antiretroviral therapy and drug resistance in HIV type 2 infection","volume":"102","author":"Menendez-Arias","year":"2014","journal-title":"Antivir Res"},{"key":"10.1016\/j.jmii.2026.07.004_bib67","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/cid\/civ124","article-title":"Dolutegravir in HIV-2-infected patients with resistant virus to first-line integrase inhibitors from the French named patient program","volume":"60","author":"Descamps","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib68","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/jac\/dkx210","article-title":"CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study","volume":"72","author":"Wittkop","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2026.07.004_bib69","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cid\/ciy245","article-title":"First-line raltegravir\/emtricitabine\/tenofovir combination in HIV-2 infection: a phase 2, non-comparative trial (ANRS 159 HIV-2)","volume":"67","author":"Matheron","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib70","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciy324","volume":"67","author":"Ba","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib71","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/jac\/dkz007","article-title":"HIV-2 Spanish Study Group. Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain","volume":"74","author":"Requena","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2026.07.004_bib72","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/cid\/ciad339","article-title":"Safety and efficacy of triple therapy with dolutegravir plus 2 nucleoside reverse transcriptase inhibitors in treatment-naive HIV type 2 patients: results from a 48-week phase 2 study","volume":"77","author":"Pacheco","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib73","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1016\/S2352-3018(24)00085-7","article-title":"FIT-2 study group. Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial","volume":"11","author":"Eholie","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2026.07.004_bib74","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/cid\/ciae447","article-title":"Immuno-virological and clinical follow-up of persons with HIV-2 (PWHIV-2) receiving bictegravir\/emtricitabine\/tenofovir alafenamide fumarate (BIC\/FTC\/TAF): a retrospective Study","volume":"80","author":"Joly","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cid\/ciae650","article-title":"Rapid selection of HIV-2 capsid mutations in salvage therapy with lenacapavir-containing regimen","volume":"81","author":"Montrouge","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib76","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/pathogens10111377","article-title":"Human immunodeficiency virus type 2: the neglected threat","volume":"10","author":"Ceccarelli","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.jmii.2026.07.004_bib77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/088922204322996590","article-title":"Are fusion inhibitors active against all HIV variants?","volume":"20","author":"Poveda","year":"2004","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jmii.2026.07.004_bib78","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01299-18","article-title":"In vitro antiviral activity of cabotegravir against HIV-2","volume":"62","author":"Smith","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2026.07.004_bib80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hiv.70120","article-title":"EACS Governing Board. Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025","volume":"27","author":"Ambrosioni","year":"2026","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hiv.13204","article-title":"British HIV Association guidelines for the management of HIV-2, 2021","volume":"22","author":"Reeves","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib83","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciaa277","article-title":"University of Washington\u2013Senegal HIV-2 Study Group. Long-term experience and outcomes of programmatic antiretroviral therapy for HIV type 2 infection in Senegal, West Africa","volume":"72","author":"Raugi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0005743","article-title":"University of Washington-Senegal HIV-2 Study Group. Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: evaluating genotypic HIV-2 drug resistance tools","volume":"6","author":"Raugi","year":"2026","journal-title":"PLOS Glob Publ Health"},{"key":"10.1016\/j.jmii.2026.07.004_bib85","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/596504","article-title":"University of Washington-Dakar HIV-2 Study Group. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resource-limited West Africa","volume":"48","author":"Gottlieb","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib86","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/cid\/ciaf110","article-title":"HIV-2 EU-Supporting standardized HIV-2 drug resistance interpretation: an update","volume":"81","author":"Charpentier","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib87","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/infdis\/jiaa026","article-title":"Expanded spectrum of antiretroviral-selected mutations in HIV type 2","volume":"221","author":"Tzou","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib88","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/cid\/ciad695","article-title":"Salvage therapy including foscarnet and ibalizumab for multidrug-resistant HIV type 2 infection","volume":"78","author":"Bachelard","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib89","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/jac\/dkr164","article-title":"Drug resistance mutations in patients infected with HIV-2 living in Spain","volume":"66","author":"Trevi\u00f1o","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2026.07.004_bib90","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/COH.0000000000000469","article-title":"Fostemsavir: a new CD4 attachment inhibitor","volume":"13","author":"Cahn","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib91","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/COH.0000000000000709","article-title":"Doravirine: its role in HIV treatment","volume":"17","author":"Stockdale","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib92","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/infdis\/jiad562","article-title":"Antiviral activity of lenacapavir against HIV type 2 (HIV-2) isolates and drug-resistant HIV-2 mutants","volume":"229","author":"Smith","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40265-020-01258-3","article-title":"Ibalizumab: a review in multidrug-resistant HIV-1 infection","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jmii.2026.07.004_bib94","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/QAD.0000000000003218","article-title":"ANRS CO5 HIV-2 cohort. Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates","volume":"36","author":"Le Hingrat","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib95","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3018(19)30408-4","article-title":"Tough requirements for new antiretroviral drugs","volume":"7","author":"de Mendoza","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jmii.2026.07.004_bib96","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00744-17","article-title":"University of Washington\u2013Dakar HIV-2 Study Group. MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine) exhibits potent activity against HIV-2 isolates and drug-resistant HIV-2 mutants in culture","volume":"61","author":"Wu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2026.07.004_bib97","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.jmii.2026.07.004_bib98","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-022-30902-7","article-title":"Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation","volume":"13","author":"Deodhar","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmii.2026.07.004_bib99","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41563-020-0731-7","article-title":"Long acting antiretroviral therapy","volume":"19","author":"Soriano","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.jmii.2026.07.004_bib100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14740338.2017.1343300","article-title":"Dual antiretroviral therapy for HIV infection","volume":"16","author":"Soriano","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jmii.2026.07.004_bib101","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/hiv.70063","article-title":"Use of dual antiretroviral therapy in individuals with different serological patterns for hepatitis B: what are the risks? What are the clinical implications?","volume":"26","author":"Kaya","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.jmii.2026.07.004_bib102","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00002030-199904160-00011","article-title":"Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection","volume":"13","author":"Norrgren","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib103","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1097\/00002030-200111230-00015","article-title":"Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data","volume":"15","author":"Greenberg","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1086\/598987","article-title":"HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia","volume":"48","author":"G\u00fcnthard","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2026.07.004_bib105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0956462420901969","article-title":"HIV-1 superinfection in a patient with known HIV-2 a case report","volume":"31","author":"Ring","year":"2020","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib106","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1097\/QAD.0000000000002338","article-title":"Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain","volume":"33","author":"Requena","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib107","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/QAD.0b013e328300a33d","article-title":"Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?","volume":"22","author":"da Silva","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jmii.2026.07.004_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283602","article-title":"Molecular confirmation of HIV-1 and HIV-2 co-infections among initially serologically dually-reactive samples from patients living in West Africa","volume":"18","author":"Tchounga","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2026.07.004_bib109","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/trstmh\/trab165","article-title":"Mother-to-child HIV-2 transmission: comparison with HIV-1 and evaluation of factors influencing the rate of transmission. A systematic review","volume":"116","author":"Ter Schiphorst","year":"2022","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.jmii.2026.07.004_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107076","article-title":"The incidence of HIV-2 infection in Spain is declining - a registry data analysis","volume":"146","author":"de Mendoza","year":"2024","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118226000903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118226000903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:40:51Z","timestamp":1789702851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118226000903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":108,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1684118226000903"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2026.07.004","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is the HIV-2 pandemic going extinct 40 years after virus discovery?","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}